Background and Objective: Osteoarthritis [OA] is one of the most common joint disease which has led to great morbidity and disability. Symptomatic Slow acting drugs for osteoarthritis which includes glucosamine sulphate and related compounds, chondroitin sulphate, and diacerein have been found to provide symptom relief and possible structure modifying effects in OA knee. This study compared the efficacy and safety of chondroitin sulphate with glucosamine and diacerein in Kellgren Lawrence grade II & III OA knee patients.
O steoarthritis [OA] one of the most common joint disease has been a burden to the healthcare society both physical and psychological. The reported prevalence of OA in India is 22-39% which accounts for 30% of all rheumatological problems. 1 Indians have a higher incidence of OA of the knee joint, while involvement of the hip joint is less common , in comparison to Western populations. 2 This has led to great morbidity and disability in the community OA can be managed by both nonpharmacological and pharmacological interventions. The non-pharmacological interventions includes weight reduction, education programs, exercise, and lifestyle changes; pharmacological treatments includes paracetamol, nonsteroidal anti-inflammatory drugs [NSAIDs] , topical medication and invasive interventions like intraarticular injections, lavage. 3 These are only palliative and provide only symptomatic relief.
NSAIDs are the most commonly prescribed drugs for OA. They have an advantage of providing symptomatic relief but do not prevent progression Patients were randomised using randomization tables generated using MS Excel with rand function. They were allotted to either group A -tablet chondroitin sulphate (400 mg) with glucosamine (500 mg) to be taken thrice a day after food or group B -capsule diacerein 50 mg, twice a day orally after food.
WOMAC Index was used for clinical assessment of the patients. It is a functional assessment scale, which contains 24 questions (Q). For pain (Q1-5), stiffness (Q6-7), and physical function difficulty (Q8-24) pertaining to the knee joint. The response was graded on a qualitative scale (0-none, 1-mild, 2 -moderate, 3 -severe, 4-extreme). The maximum score could be 96. 12 Western Ontario and McMaster University Osteoarthritis Index (WOMAC) assessment and radiological assessment of knee(s) was done at the first visit. Tablet paracetamol was given to the patients for pain relief during the initial one week of the study period after which patient was allowed to take it as and when needed. Patients were advised to come for follow up on week 3 (visit 2), week 12 (visit 3), week 24 (visit 4) and WOMAC index assessment for clinical efficacy was done. The patients were advised to report immediately on experiencing any adverse event during the study period. At the last visit of study period (24 th week) drug therapy was withdrawn.
Statistical analysis was carried out using Microsoft Excel 2010. The p value < 0.05 was taken as significant. Data expressed as mean ±SD and proportions. Student t test was used to compare data between the groups with respect to their means. Chi-square test was used to compare data between the groups with respect to their proportions
ReSuLtS
A total of 88 patients were screened for eligibility, out of which 75 patients who satisfied the criteria were included in the study and were randomized to either group A or group B.
A total of 60 patients completed the study. Fifteen patients were lost to follow-up (7 in group A and 5 in group B) and 3 in group B discontinued the drug due to diarrhoea.
Baseline characteristics of the patients are presented in Table 1 . There were no significant differences between groups in the baseline parameters. of the disease. 4 NSAIDs also have disadvantages like causing serious adverse effects, especially on long term use. 5 NSAIDs should be considered only in patients not responsive to paracetamol. 6 For these reasons "Symptomatic Slow Acting Drugs for Osteoarthritis" (SYSADOA) which includes chondroitin sulphate, glucosamine sulphate and diacerein which would provide both symptomatic improvement and disease modifying effects in OA was found to be effective and safe in the management of OA. 7 Chondroitin sulphate and Glucosamine are glycosaminoglycans present in the articular cartilage and plays a major role in the structure and functioning of joints. Hence, products containing these are believed to have positive effects on osteoarthritic joints and to delay the cartilage deterioration. 8 Diacerein is a new anti-inflammatory drug found to act by inhibiting interleukin β(ILβ) and it has the advantage of lacking the side effects of classical NSAIDs. 9 Over the past 10 years the cartilage constituents' Chondroitin and Glucosamine have been increasingly prescribed by general practitioners and rheumatologists all over the world. 10 Many clinical trials have proven their safety and efficacy along with possible structure modifying effects. 7 Hence this study was planned to analyse the efficacy of Chondroitin sulphate with Glucosamine versus Diacerein in patients with OA
mAteRIAL AND metHoDS
This study was conducted in Mahatma Gandhi Medical College and Research Institute, Pondicherry. The study was approved by Institutional Human ethics Committee. Written informed consent was taken from all the study participants.
Inclusion criteria were all patients of either sex above 45 years of either sex with symptomatic OA with Kellgren-Lawrence (KL) Grade II and III 11 OA of knee(s), Exclusion criteria were patients who had previous or ongoing SYSADOA treatment, patients with Inflammatory arthritis or post-traumatic arthritis knee. The patients were enrolled to study after satisfying the inclusion criteria, and signed the informed consent form. At the time of screening a detailed medical history, general physical examination, and local examination of the knee(s) were done. X ray of both knees was carried out at the beginning of the study. The qualified knee(s) were checked and recorded as the index joint. Table 2 ). Thus the efficacy in group A on function improvement with WOMAC scale was greater than group B. These changes in WOMAC scores in group A and B (Figure 1) 
DISCuSSIoN
SYSADOA have a slow onset of clinical efficacy when compared to NSAIDS and once the administration is stopped they show carry over effect. The main rationale for using SYSADOA is to reduce the use of NSAIDs thereby limiting the risk of upper gastro intestinal track erosions, ulcers and deleterious renal effects in elderly patients. 13 The treatment groups had symptomatic OA with mean WOMAC score of > 60 at baseline. Our study showed improvement in WOMAC scores during the course of the treatment till 24 weeks i.e. the end of the study.
The findings of WOMAC scores in group A patients was similar to Glucosamine/chondroitin Arthritis Intervention Trial. 14 The findings of efficacy parameters WOMAC index of diacerein was similar to an Indian study. 15 The same was also discussed in a review of clinical efficacy and safety of diacerein in OA in 2010. 16 The symptomatic benefit provided by diacerein in terms of pain reduction was found to be minimal which was discussed in an earlier Cochrane study. 17 In contrast to the above findings, Wandel et al in his study had shown that chondroitin sulphate and glucosamine did not reduce the joint pain. 18 Irrespective of the differing healthcare policies and treatment standards internationally, our aim should be to identify the best-available treatment practices for knee.
The limitations of our study were small sample size, limited period of study and lack of a control group.
Thus further studies with large sample size with long term follow up have to be done to confirm the findings of our study.
We conclude that chondroitin sulphate with glucosamine combination is effective in the treatment of osteoarthritis knee compared to diacerein as the combination showed improvement of symptoms and functional disability as assessed by WOMAC index.
